Finance

Lists
Why is FAE up 3,04%?
Dive Deeper
FAE:BME
FAES Farma SA
€4,75
+3,04%
(+0,14) 1D
6 Okt., 17:37:04 GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for FAE...
Open
€4,62
High
€4,76
Low
€4,62
Mkt. cap
1,47 mjd
Avg. vol.
179,36 k
Volume
194,82 k
Dividend
2,69%
Quarterly dividend
€0,03
Ex-dividend date
02 Jul. 2026
P/E ratio
17,67
52-wk high
€5,44
52-wk low
€4,32
EPS
€0,27
Shares outstanding
316,22 m
No. of employees
3 k
Open
€4,62
High
€4,76
Low
€4,62
Mkt. cap
1,47 mjd
Avg. vol.
179,36 k
Volume
194,82 k
Dividend
2,69%
Quarterly dividend
€0,03
Ex-dividend date
02 Jul. 2026
P/E ratio
17,67
52-wk high
€5,44
52-wk low
€4,32
EPS
€0,27
Shares outstanding
316,22 m
No. of employees
3 k
News stories
From web sources and news partners
Profile
Faes Farma, originally Fábrica Española de Productos Químicos y Farmacéuticos, is a Spanish pharmaceutical company based in the Lamiaco district of Lejona in Biscay. Founded on 29 July 1933 by the Serra family with an initial capital of two million pesetas, it pioneered the development of various therapeutic compounds and has been listed on the Madrid Stock Exchange since the 1940s. Faes Farma’s headquarters, production facilities, and R&D center are located in Lejona, with additional offices in Madrid and Barcelona. The group also operates subsidiaries in Portugal, Italy, Mexico, Guatemala, Colombia, Chile, Peru, Bolivia, Ecuador and Nigeria, and maintains an animal nutrition and health division under the name FARM Faes. Wikipedia
About FAES Farma SA
CEO-
Employees2,61 k
Founded29 Jul. 1933
Headquarters-
SectorPharmaceutical industry
Websitefaesfarma.com
Last report
30 Jul. 2026
Fiscal period
Q2 2026
EPS / Est. (EUR)
€0,09 / -
0,00%miss
Revenue / Est. (EUR)
401,85 m / 189,65 m
+111,89%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in EUR
Loading Previous Earnings...
Revenue
Net income
All values in EUR
Sep. 2025
Des. 2025
Mrt. 2026
Jun. 2026
Revenue
146,61 m
172,99 m
200,07 m
191,39 m
Cost of goods sold
52,40 m
73,44 m
61,59 m
60,25 m
Cost of revenue
52,40 m
73,44 m
61,59 m
60,25 m
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
27,36 m
80,84 m
45,67 m
44,06 m
Operating expense
68,06 m
98,44 m
100,13 m
98,54 m
Total operating expenses
120,47 m
171,88 m
161,72 m
158,78 m
Operating income
26,14 m
1,11 m
38,35 m
32,61 m
Other non operating income
401,00 k
1,02 m
-
-
EBT including unusual items
25,18 m
-1,39 m
36,36 m
30,47 m
EBT excluding unusual items
25,18 m
-1,65 m
36,36 m
30,47 m
Income tax expense
3,75 m
-7,43 m
5,49 m
4,32 m
Effective tax rate
14,91%
534,46%
15,10%
14,19%
Other operating expenses
33,65 m
7,21 m
44,62 m
44,44 m
Net income
21,23 m
6,07 m
30,79 m
26,10 m
Net profit margin
14,48%
3,51%
15,39%
13,64%
Earnings per share
-
-
-
-
Interest and investment income
-
-
-
1,41 m
Interest expense
-1,99 m
-3,51 m
-1,99 m
-3,58 m
Net interest expenses
-1,99 m
-3,51 m
-1,99 m
-2,18 m
Depreciation and amortization charges
7,05 m
10,39 m
9,83 m
10,04 m
EBITDA
30,15 m
6,94 m
44,19 m
40,50 m
Gain or loss from assets sale
-
-
-
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google-programme